La incidencia de metástasis endobronquiales secundarias a tumores sólidos es baja. Los tumores primarios que con más frecuencia producen metástasis endobronquiales son la mama, el colon y los tumores renales. Normalmente se presentan como una manifestación tardía de la enfermedad con un pronóstico malo y por su forma inespecífica de presentación precisan diagnóstico diferencial con los tumores pulmonares primarios (AU)
Endobronchial metastases secondary to extrapulmonary solid malignant tumours are rare. The most frequent primary tumours associated with endobronchial involvement are breast, colon and renal cell carcinoma. Endobronchial metastases usually appear later with a poorer prognosis and require differential diagnosis from a primary lung cancer (AU)
Humans , Female , Adult , Dyspnea/complications , Dyspnea/diagnosis , Dyspnea/drug therapy , Breast Neoplasms/complications , Breast Neoplasms/diagnosis , Neoplasm Metastasis/diagnosis , Neoplasm Metastasis/physiopathology , Spirometry/methods , Radiography, Thoracic/methods , Bronchoscopy/methods , Neoplasms, Multiple Primary/complications , Diagnosis, Differential , Neoplasms, Ductal, Lobular, and Medullary/complications , Neoplasms, Ductal, Lobular, and Medullary/diagnosis , Breast Neoplasms/drug therapy , Breast Neoplasms/radiotherapy
Prostate carcinoma is currently the third cause of cancer death among the male population, showing a clear trend to increase in terms of the number of cases detected over the last few years. 180 clinical reports of patients diagnosed with metastatic prostate cancer since 1983 were revised. The study included 60 cases with a correct extension diagnosis, as well as clinical and analytical follow up. Patients were divided into 3 groups based on the treatment received: maximum androgen blockade (group A), ablative treatment with diethylstilbestrol or orchiectomy (group B), and patients with other treatment (chemotherapy). Survival results were compared with due consideration to the prognostic factors. The comparative statistical analysis done on patients included in group A and B relative to age at diagnosis, time interval between onset of symptoms and diagnosis, analytical data at time of diagnosis, duration of treatment response and overall survival yielded significant differences in the variables studied. No conclusive data can be drawn from the results of our series as to whether treatment with maximum androgen blockade is superior to ablative treatment, therefore it is still necessary to carry out further studies to define which is the best therapeutical tool for use in prostate cancer.
Prostatic Neoplasms/therapy , Aged , Aged, 80 and over , Antineoplastic Agents, Hormonal/therapeutic use , Humans , Male , Middle Aged , Neoplasm Staging , Pain/etiology , Prostatic Neoplasms/complications , Prostatic Neoplasms/mortality , Prostatic Neoplasms/pathology , Spain/epidemiology
